Recursion Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : All right. I guess there's a lot of data out there in drug discovery, lots of upcoming AI technologies, machine learning platforms. So how is Recursion different from some of your peers? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 26, 2023 / 3:05PM, RXRX.OQ - Recursion Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay. And given this field is continuously evolving, how do you maintain leadership in this space? Like what are you doing different?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay. And back in July, you announced a partnership with NVIDIA. So maybe talk about that partnership, what it entails, and some of the resources that you may have used already in your technology.

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay, and you talked about the Bayer and other pharma partnerships as well. So can you talk about the value that you are creating for them?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay, and are you seeing more interest from some of the large-cap pharma and biotechs to do more partnership? And what do you see as a typical league structure?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay. And coming to your internal pipeline, maybe if you can talk about some of the different assets you have in development.

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Right. And you talked about different disease areas and a lot of Phase 2 readouts over the next 12 to 18 months. So maybe, what program or readout are you most excited about and could create the biggest value for the company?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : And between the internal assets, as well as the external partnerships, how are you thinking about prioritizing these opportunities?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay. And on the capital situation, talk about the cash runway and any upcoming milestones for the company?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay. And I guess, where do you see Recursion in the next 12 to 18 months? And why do you think AI is just not a hype and drug discovery?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Okay, any audience questions? Unidentified Participant 1 How are the options on your pharma partners, how are they structured and tied? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 26, 2023 / 3:05PM, RXRX.OQ - Recursion Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference